Michael Ouk1, Jodi D Edwards1, Jessica Colby-Milley1, Alexander Kiss1, Walter Swardfager2, Marcus Law1. 1. Hurvitz Brain Sciences Program (Ouk, Colby-Milley, Swardfager), Sunnybrook Research Institute, University of Toronto; Departments of Pharmacology & Toxicology (Ouk, Swardfager) and Family & Community Medicine (Law), University of Toronto, Toronto, Ont.; University of Ottawa Heart Institute (Edwards); School of Epidemiology and Public Health (Edwards), University of Ottawa, Ottawa, Ont.; ICES (Kiss), Toronto, Ont. 2. Hurvitz Brain Sciences Program (Ouk, Colby-Milley, Swardfager), Sunnybrook Research Institute, University of Toronto; Departments of Pharmacology & Toxicology (Ouk, Swardfager) and Family & Community Medicine (Law), University of Toronto, Toronto, Ont.; University of Ottawa Heart Institute (Edwards); School of Epidemiology and Public Health (Edwards), University of Ottawa, Ottawa, Ont.; ICES (Kiss), Toronto, Ont. w.swardfager@utoronto.ca.
Abstract
BACKGROUND: Cervical cancer screening reduces disease-specific mortality. This study aimed to estimate whether bipolar disorder or schizophrenia is associated with disparities in cervical cancer screening rates. METHODS: This was a retrospective population-based matched case-cohort study of community-dwelling women aged 19-69 in Ontario using linked health administrative databases. We used odds ratios (ORs), hazards ratios and rate ratios (RRs) adjusted for demographic characteristics and relevant comorbidities to compare cervical cancer screening outcomes between women with a diagnosis of bipolar disorder or schizophrenia to women without that history matched on key demographic characteristics, between 2003 and 2015. RESULTS: In total, 1 245 457 women were identified for inclusion in the analyses, 119 948 with a diagnosis of bipolar disorder or schizophrenia, and 1 125 509 without. Over a median follow-up duration of 12.5 years, women with the exposure were 36% less likely to be screened (OR 0.64, 95% confidence interval [CI] 0.64-0.65) than those without, and they took longer to undergo screening (median 18.98 mo v. 16.63 mo; χ2 = 3718.2, p < 0.001). They were also screened less frequently (median 6.16 yr v. 4.69 yr per screen; RR 0.85, 95% CI 0.84-0.85). These effects were consistent after we excluded the 86 475 women (6.9%) with suspected major depressive disorder, and they were larger for the 59 141 women (4.7%) not attached to a family physician. INTERPRETATION: Women with bipolar disorder or schizophrenia were less likely to undergo cervical cancer screening, their screening was delayed, and they were screened at a lower rate compared to women without this psychiatric history. This practice gap suggests a need to further address barriers to screening, including access to a family physician, among women with bipolar disorder or schizophrenia. Copyright 2020, Joule Inc. or its licensors.
BACKGROUND: Cervical cancer screening reduces disease-specific mortality. This study aimed to estimate whether bipolar disorder or schizophrenia is associated with disparities in cervical cancer screening rates. METHODS: This was a retrospective population-based matched case-cohort study of community-dwelling women aged 19-69 in Ontario using linked health administrative databases. We used odds ratios (ORs), hazards ratios and rate ratios (RRs) adjusted for demographic characteristics and relevant comorbidities to compare cervical cancer screening outcomes between women with a diagnosis of bipolar disorder or schizophrenia to women without that history matched on key demographic characteristics, between 2003 and 2015. RESULTS: In total, 1 245 457 women were identified for inclusion in the analyses, 119 948 with a diagnosis of bipolar disorder or schizophrenia, and 1 125 509 without. Over a median follow-up duration of 12.5 years, women with the exposure were 36% less likely to be screened (OR 0.64, 95% confidence interval [CI] 0.64-0.65) than those without, and they took longer to undergo screening (median 18.98 mo v. 16.63 mo; χ2 = 3718.2, p < 0.001). They were also screened less frequently (median 6.16 yr v. 4.69 yr per screen; RR 0.85, 95% CI 0.84-0.85). These effects were consistent after we excluded the 86 475 women (6.9%) with suspected major depressive disorder, and they were larger for the 59 141 women (4.7%) not attached to a family physician. INTERPRETATION:Women with bipolar disorder or schizophrenia were less likely to undergo cervical cancer screening, their screening was delayed, and they were screened at a lower rate compared to women without this psychiatric history. This practice gap suggests a need to further address barriers to screening, including access to a family physician, among women with bipolar disorder or schizophrenia. Copyright 2020, Joule Inc. or its licensors.
Authors: Joan Murphy; Erin B Kennedy; Sheila Dunn; C Meg McLachlin; Michael Fung Kee Fung; Danusia Gzik; Michael Shier; Lawrence Paszat Journal: J Obstet Gynaecol Can Date: 2012-05
Authors: Louise M Howard; Elizabeth A Barley; Elizabeth Davies; Anne Rigg; Heidi Lempp; Diana Rose; David Taylor; Graham Thornicroft Journal: Lancet Oncol Date: 2010-07-03 Impact factor: 41.316
Authors: Monique James; Melanie Thomas; Latoya Frolov; Nicholas S Riano; Eric Vittinghoff; Dean Schillinger; John W Newcomer; Christina Mangurian Journal: Psychiatr Serv Date: 2017-04-17 Impact factor: 3.084
Authors: Christopher Lo; Andrew Calzavara; Paul Kurdyak; Lisa Barbera; Frances Shepherd; Camilla Zimmermann; Malcolm J Moore; Gary Rodin Journal: Can Fam Physician Date: 2013-03 Impact factor: 3.275
Authors: Aisha K Lofters; Amy Mark; Monica Taljaard; Michael E Green; Richard H Glazier; Simone Dahrouge Journal: BMC Fam Pract Date: 2018-08-29 Impact factor: 2.497
Authors: Eric I Benchimol; Liam Smeeth; Astrid Guttmann; Katie Harron; David Moher; Irene Petersen; Henrik T Sørensen; Erik von Elm; Sinéad M Langan Journal: PLoS Med Date: 2015-10-06 Impact factor: 11.069